Review Identifies Proteasomal Switch and Age-Related Proteostatic Decay as Key Drivers of Influenza Severity and Inflammaging

A scientific review outlines how age-related immunoproteasome decay interacts with Influenza A infection to drive acute lung injury and inflammaging, proposing a biphasic framework for timing-dependent proteasomal therapeutic modulation.

Researchers published a comprehensive review examining the host-pathogen competition for proteostatic control during Influenza A virus (IAV) infection.

The paper characterizes the 'proteasomal switch,' a process where constitutive proteasome subunits (β1, β2, β5) are replaced by inducible subunits (β1i, β2i, β5i) to form the immunoproteasome (iP).

The authors describe how the immunoproteasome works alongside the broader ubiquitin-proteasome system, endoplasmic reticulum-associated degradation, and autophagic pathways to mitigate oxidative and proteotoxic stress in infected cells.

The review details how age-related decay of these clearance networks, combined with viral subversion tactics, exacerbates acute lung injury and contributes to the chronic inflammatory state known as inflammaging.

By linking acute viral pathogenesis with systemic, age-associated cellular clearance decline, the research provides a clear biological framework for the high susceptibility of older populations to severe respiratory pathogens.

The work introduces a timing-dependent therapeutic paradigm, balancing the theoretical benefits of early-stage immunoproteasome activation against preclinically supported late-stage β5i inhibition.

The identification of the immunoproteasome (specifically the β5i subunit) as a target for modulating age-related tissue degradation highlights a distinct, early-stage opportunity for longevity therapeutic developers focused on proteostasis.

The translational complexity of timing-dependent biphasic interventions represents a high regulatory and clinical design hurdle for future drug candidates targeting these pathways.

Preclinical studies evaluating the safety and therapeutic index of selective late-stage β5i inhibitors in animal models of severe influenza and chronic lung injury.